LineVest
ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash
GSK and Eli Lilly upfront payments clear from receivables to cash, leaving ABL Bio debt-free on a net basis and compressing the quarterly loss to its lowest year-on-year level in two years.
Source: Q1 2026 Quarterly Report (11th Fiscal Year, January 1–March 31, 2026) — Filed May 8, 2026 with DART | Consolidated Financial Statements (ABL Bio Inc. + ABL Bio USA + NEOK Bio) | Unit: ₩ billions
“ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash”
This article became available on July 26, 2026. Subscribe to read in full, or wait until October 24, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read ABL Bio's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the ABL Bio reportReading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.
